Efficacy of Sensory Stimulation in Intensive Care Unit Patients: A Systematic Review and Meta-analysis.

Dimens Crit Care NursJul 28, 2026 (epub)
Clinical ResearchAnesthesiologyEmergency MedicineInternal Medicine (General)

Chunyan Han, Xiujie Sun, Yanan Zhu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effects of sensory stimulation (SS) on ICU patients, analyzing 22 randomized controlled trials with 1,522 participants. The study found that SS significantly improved the level of consciousness (MD: 2.09) and reduced both the incidence (OR: 0.33) and duration of delirium (MD: -2.63), while also shortening awakening time (MD: -7.39) compared to routine care.

Key findings

  • SS improved the level of consciousness (MD: 2.09; P < .001).
  • SS reduced the incidence of delirium (OR: 0.33; P < .001).
  • SS decreased the duration of delirium (MD: -2.63; P < .001).
  • SS shortened awakening time (MD: -7.39; P < .001).

Why it matters

The findings suggest that implementing sensory stimulation in ICU settings may enhance patient outcomes by improving consciousness and reducing delirium, which are critical factors in recovery and overall patient care.

Source

PubMed · PMID 42520766

Published in Dimens Crit Care Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Anesthesiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.